Jennifer Bourque - Researcher Profile

Publications

2 shown

Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

Amita Patnaik , Mark A. Socinski , Matthew A. Gubens +7 more

8011 Background: Pembro is a potent anti–PD-1 monoclonal antibody. IPI, an anti–CTLA-4 antibody, has shown activity in advanced NSCLC. In melanoma, combined anti–PD-1 and anti–C...

2015 Journal of Clinical Oncology 68 citations

Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.

James Stevenson , Leena Gandhi , Matthew A. Gubens +10 more

8031 Background: As monotherapy, the anti–PD-1 antibody pembro has shown robust antitumor activity in advanced NSCLC patients (pts). KEYNOTE-021 evaluated the safety, tolerabili...

2015 Journal of Clinical Oncology 34 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 102
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

Google Scholar

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.